USP14 and cancer: Upon USP14 knockdown, cancer cells exhibited a significantly enhanced response to oxaliplatin treatment, as evidenced by a marked increase in apoptosis by 37% (LoVo) and 25% (SW48) (Figs. 2d and S2a, b).